MedTrace Logo

The FAVOR III China Study

NCT03656848 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3847

Last updated 2022-12-20

No results posted yet for this study

Summary

The overall purpose of the FAVOR III China trial is to investigate if a strategy of quantitative flow ratio (QFR)-guided percutaneous coronary intervention (PCI) yields superior clinical outcome and cost-effectiveness compared to a strategy of standard coronary angiography-guided PCI in evaluation of patients with coronary artery disease.

Conditions

  • Coronary Artery Disease
  • Myocardial Ischaemia
  • Coronary Circulation
  • Coronary Stenosis
  • Percutaneous Coronary Intervention

Interventions

DIAGNOSTIC_TEST

Angiography

Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries

DIAGNOSTIC_TEST

QFR

QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.

Sponsors & Collaborators

  • China National Center for Cardiovascular Diseases

    lead OTHER_GOV

Principal Investigators

  • Bo Xu, MBBS · Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences

  • Shubin Qiao, MD · Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-25
Primary Completion
2021-02-19
Completion
2025-02-19

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03656848 on ClinicalTrials.gov